ARCHIVES

Adverse data from cancer prevention trial makes Merck withdraw Vioxx from market. Researchers discuss implications for other cancer prevention trials.

This article is from The Cancer Letter archive.

Vol. 30 No. 39 | October 15, 2004

Download PDF Visit The Full Archive

Related Articles

Momentum Continues For Private Development Of Free Standing Cancer Centers

July 19, 1985

In Brief: Sandor Eckhardt Is New UICC President; New Delhi Is Site Of 1994 UICC Meeting

August 31, 1990

Firm Buys Rights To NKT Cells From Beth Israel Deaconess.

July 28, 2000

In Brief: Hawaii Center Searching For New Director: Rosenberg Denies Report He’s Going To Tampa

June 7, 1985

Other DCT Concepts Approved By Board

February 26, 1988

USC Scientists Says It’s Time Nobelists Recognize Value of Cancer Program

February 10, 1978